Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.64 |
| ▸ | MET | P08581 | 6/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.61 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.61 |
| ▸ | SRC | P12931 | 4/20 | 0.61 |
| ▸ | KIT | P10721 | 4/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | NEK2 | P51955 | 3/20 | 0.61 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | YES1 | P07947 | 3/20 | 0.61 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.61 |
| ▸ | PLK4 | O00444 | 2/20 | 0.61 |
| ▸ | RIOK3 | O14730 | 2/20 | 0.61 |
| ▸ | GAK | O14976 | 2/20 | 0.61 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.61 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147096 | 0.97 | KDR (0.69) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL142619 | 0.94 | KDR (0.69) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL147422 | 0.90 | KDR (0.66) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL145248 | 0.89 | KDR (0.63) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL141110 | 0.89 | KDR (0.67) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL146263 | 0.89 | KDR (0.71) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL145040 | 0.88 | KDR (0.62) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL143827 | 0.86 | PRKAA1 (0.59) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL148704 | 0.86 | KDR (0.62) | KDRPDGFRBFGFR1METPRKAA2 | |
| SCHEMBL147111 | 0.86 | KDR (0.60) | KDRPDGFRBFGFR1METPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.